Psychosis and schizophrenia, first-episode presentation, antipsychotics, involuntary treatment

1. Definition and clinical relevance

Schizophrenia is a chronic psychotic disorder characterised by disturbances in thought, perception and behaviour. First-episode psychosis most commonly presents in young people under 35 years with positive symptoms (delusions, hallucinations, thought disorder) and frequently lack of insight.

Neurodevelopmental origins:

• Often foreshadowed by delayed developmental milestones
• Impaired language and cognitive development
• Associated with perinatal morbidity in birth history

Clinical course:

• Chronic, often deteriorating trajectory
• Significant impairment across self-care, social relationships and work
• Family history of mental illness is common

Suicide risk:

• 10 to 14% report deliberate self-harm or suicide attempt prior to presentation
• Period immediately before first presentation carries increased risk
• Suicide rates remain high after treatment begins (approximately 2.9 to 11% at one year)
• Early identification, risk assessment and engagement are critical

2. Key values, thresholds and decision rules

• Most patients with schizophrenia respond to an antipsychotic; however, the majority will relapse within two years if they stop medication.
• Around 25% of patients do not respond adequately despite being adherent, and these patients should be switched to alternative therapy, ultimately including clozapine.

Antipsychotic drug considerations (grounded):

Emergency sedation while awaiting admission (grounded doses):

• Reduce doses in elderly patients.
• Avoid chlorpromazine if the patient is epileptic, has been drinking alcohol, or has taken barbiturates.

3. Approach: presentation and differential

History

• The initial approach frequently comes from a relative or friend rather than the patient.
• Ask specifically about thoughts and perceptions.

Enquire about characteristic first-rank type symptoms:

• Thought disorder: thought broadcast, withdrawal, insertion or interruption; thought blocking (abrupt, involuntary interruption of the stream of thought, sometimes mid-sentence).
• Delusional perception.
• Passivity phenomena: feelings or actions experienced as made or influenced by external agents.
• Passive thought control: thought insertion strongly associated with schizophrenia.
• Elicit any history of drug misuse.
• Take a social and developmental history using open-ended questions, noting birth history (association with perinatal morbidity) and early development.
• Ask about prodromal features: social isolation or withdrawal, deterioration in functioning at home, school, grooming and hygiene, lack of energy, hypersomnia, inappropriate or dulled affect.

Crucially, assess risk to self and others, given the high rate of self-harm and suicide in this population.

Examination

Assess behaviour and appearance. Look for evidence of:

• Deteriorating self-care.
• Loss of affect (blunted or restricted affect is characteristic of schizophrenia).
• Poverty of thought.
• Social withdrawal.
• Inappropriate affect (responses not appropriate to the matter discussed).

Differential

• Bipolar disorder (mania): high or low mood, agitation, inappropriate behaviour, reduced sleep, increased energy, irritability, suspiciousness, rapid thought and speech, grandiose delusions. Often confused with schizophrenia in adolescence. Bipolar disorder should be distinguished from schizophrenia, major depression with agitation, PTSD, disruptive behaviour disorder, and mood disorder or delirium secondary to a medical condition (for example hyperthyroidism, porphyria) or intoxication (for example amphetamines, phencyclidine).
• Delirium (including hyperactive delirium in older people): agitation and hallucinations can be mistaken for late-onset schizophrenia or mania.
• Substance intoxication / drug misuse.
• Dementia: contrast is useful. Dementia has middle-aged/elderly onset, always-impaired memory, and rare delusions/uncommon hallucinations; schizophrenia has young onset, usually unaffected memory, and frequent delusions and hallucinations.
• Severe depression (pseudodementia) in older patients.

4. Investigations

Bedside

• Full mental state examination, documenting mood, affect (blunted/restricted/inappropriate), thought form and content, and perceptual disturbance.
• Structured risk assessment for self-harm and harm to others.

Bloods

• Investigations should be guided by the clinical picture, particularly to exclude organic mimics such as delirium.
• A reasonable organic screen includes FBE, U&E, glucose, calcium, liver function tests, cardiac enzymes, ESR, CRP, oxygen saturation and MSU where indicated.

Baseline bloods are also required to guide and monitor antipsychotic therapy:

• eGFR before and during amisulpride (renally excreted).
• Prolactin where hyperprolactinaemia is a concern (for example amisulpride).
• Metabolic monitoring given the diverse metabolic and endocrine side-effect profile of antipsychotics, which merits regular clinician review.
• For clozapine: mandatory frequent blood counts (agranulocytosis surveillance) and clinical monitoring including for myocarditis.

Imaging

Not specifically grounded; investigation should be guided by the clinical picture to exclude organic causes.

5. Management

Step 1: Assess risk and decide on admission

• Ask whether the patient is a risk to self or others.
• If psychotic illness is suspected and the patient is at risk, arrange admission.
• Offer voluntary admission first.
• If the patient is unwilling to accept voluntary admission, use compulsory admission under the relevant state Mental Health Act.

Step 2: Manage acute agitation

• The acute phase usually requires hospitalisation.
• If sedation is needed while awaiting admission, try oral medication first (lorazepam 1 to 2 mg PO or chlorpromazine 50 to 100 mg PO).
• If refused and agitation is severe, consider lorazepam 1 to 2 mg IM or chlorpromazine 50 mg IM.
• Reduce the dose in elderly patients and avoid chlorpromazine in epilepsy, recent alcohol use, or barbiturate use.

Step 3: Antipsychotic treatment of the psychosis

Drug treatment targets the psychosis. Options include:

• First-generation (typical) antipsychotics such as haloperidol and chlorpromazine, which are effective for positive symptoms.
• Second-generation (atypical) antipsychotics such as amisulpride and aripiprazole.
• Choice is individualised, balancing efficacy against the diverse side-effect profile (metabolic, endocrine and neurocognitive), which requires regular clinician review.
• Aripiprazole causes less akathisia than first-generation agents.
• Amisulpride is a reasonable choice in post-ictal psychosis but requires eGFR monitoring in renal impairment.

Managing extrapyramidal side effects:

• Acute dystonia: an anticholinergic, for example procyclidine 5 to 10 mg IM, repeated after 20 minutes if necessary (maximum 20 mg daily).
• Drug-induced parkinsonism: an anticholinergic, for example procyclidine 2.5 mg orally three times daily, increased gradually to a maximum of 30 mg in divided doses.
• Akathisia: a benzodiazepine or a beta-blocker.
• Alternatively, consider switching from a conventional to an atypical antipsychotic.

Step 4: Depot / long-acting injectable antipsychotics

• Long-acting intramuscular ("depot") preparations allow scheduled administration by community mental health teams, assuring adherence in patients with limited insight.
• Aripiprazole is available in a depot form.

Step 5: Treatment resistance and clozapine

• Around 25% of adherent patients do not respond adequately and should be switched to alternative therapy, ultimately clozapine.
• Traditionally reserved for treatment-resistant illness, there is growing evidence that clozapine should be introduced earlier where it is safe to prescribe.
• Mortality in schizophrenia is lower in the clozapine group.
• However, all patients on clozapine require mandatory frequent blood count and clinical monitoring, given the risk of agranulocytosis (a rare, life-threatening complication affecting ~0.8% over a treatment lifetime), as well as vigilance for myocarditis, constipation and hypersalivation.

Step 6: Adjunctive treatments

ECT may be considered for schizophrenia in combination with antipsychotic medication when a rapid clinical response is an urgent priority, and may augment outcomes in treatment-resistant illness.

Step 7: Psychosocial and family support

• Drug treatment is only part of total management. Explanation and reassurance to the family, patient and family supportive care, and supportive psychotherapy across all phases are essential.
• A team approach is necessary given the devastating impact on families.
• Specialist referral is appropriate.

6. Australian-specific considerations

• Community mental health teams are central to delivering depot antipsychotics and assuring adherence in patients with limited insight.
• Compulsory (involuntary) admission is governed by the relevant state or territory Mental Health Act; the framework differs slightly between jurisdictions.
• Clozapine is prescribed under a mandatory haematological monitoring program in Australia, with regular blood counts required for continued supply.
• Specialist early psychosis services provide assertive community treatment, antipsychotic medication, psychoeducational family treatment and social skills training; these have been evaluated in first-episode psychosis.
• The elevated suicide and self-harm risk in first-episode psychosis makes structured risk assessment and rapid engagement with mental health services a priority.
• In rural and remote settings, telepsychiatry and shared-care arrangements with GPs support ongoing monitoring, especially for depot administration and metabolic surveillance.

Clinical pearls

• First presentation is typically a young person under 35 with positive symptoms and poor insight; the referral often comes from a relative, not the patient.